Published in J Cell Physiol on April 01, 2006
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell (2015) 1.88
Apigenin: a promising molecule for cancer prevention. Pharm Res (2010) 1.78
Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med (Maywood) (2009) 1.10
Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anticancer Agents Med Chem (2013) 1.00
IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett (2010) 0.95
Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer (2015) 0.93
Effects of food formulation and thermal processing on flavones in celery and chamomile. Food Chem (2013) 0.84
Antitumor activity of total flavonoids from Tetrastigma hemsleyanum Diels et Gilg is associated with the inhibition of regulatory T cells in mice. Onco Targets Ther (2014) 0.83
Endogenous enzymes, heat, and pH affect flavone profiles in parsley (Petroselinum crispum var. neapolitanum) and celery (Apium graveolens) during juice processing. J Agric Food Chem (2011) 0.81
Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma. Sci Rep (2016) 0.79
Protective Effect of Quercetin on Posttraumatic Cardiac Injury. Sci Rep (2016) 0.78
Phytochemicals for the Management of Melanoma. Mini Rev Med Chem (2016) 0.77
Apigenin, a potent suppressor of dendritic cell maturation and migration, protects against collagen-induced arthritis. J Cell Mol Med (2015) 0.77
Ethnopharmacological Significance of Eclipta alba (L.) Hassk. (Asteraceae). Int Sch Res Notices (2014) 0.76
Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett (2017) 0.75
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) (2016) 0.75
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology (2007) 2.45
Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol (2002) 2.19
Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal (2008) 2.19
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res (2005) 1.84
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res (2005) 1.69
Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res (2007) 1.65
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2009) 1.59
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem (2002) 1.56
Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res (2011) 1.53
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 1.52
Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene (2003) 1.49
A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res (2008) 1.49
Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer (2004) 1.45
The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene (2002) 1.44
Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res (2008) 1.44
A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. Cancer Prev Res (Phila) (2011) 1.43
The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clin Cancer Res (2006) 1.41
Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol (2005) 1.40
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res (2004) 1.38
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res (2005) 1.38
90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J (2004) 1.33
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene (2002) 1.33
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene (2004) 1.28
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res (2004) 1.25
Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol (2008) 1.25
Detection and analysis of spliced chimeric mRNAs in sequence databanks. Nucleic Acids Res (2003) 1.24
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A (2006) 1.22
Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res (2004) 1.22
Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res (2006) 1.20
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood (2009) 1.20
Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res (2009) 1.19
Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res (2009) 1.19
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer (2009) 1.18
Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res (2005) 1.18
Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob Agents Chemother (2006) 1.16
Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst (2005) 1.16
Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res (2010) 1.16
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res (2002) 1.16
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia (2009) 1.15
Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med (2006) 1.15
Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res (2008) 1.14
Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res (2006) 1.13
PTP-PEST phosphatase variations in human cancer. Cancer Genet Cytogenet (2006) 1.10
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest (2004) 1.10
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res (2002) 1.09
Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther (2006) 1.08
Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res (2003) 1.08
Endothelin receptors as novel targets in tumor therapy. J Transl Med (2004) 1.07
Antimetastatic activity of a preventive cancer vaccine. Cancer Res (2007) 1.07
Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. Mol Biol Cell (2010) 1.07
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res (2008) 1.06
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia (2011) 1.06
Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem (2003) 1.05
p130Cas is an essential transducer element in ErbB2 transformation. FASEB J (2010) 1.05
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res (2010) 1.05
Fucans, but not fucomannoglucuronans, determine the biological activities of sulfated polysaccharides from Laminaria saccharina brown seaweed. PLoS One (2011) 1.05
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer (2006) 1.04
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res (2007) 1.04
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol (2004) 1.04
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res (2003) 1.03
p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. Jpn J Clin Oncol (2011) 1.03
Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res (2007) 1.03
Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods. Clin Cancer Res (2006) 1.02
Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res (2005) 1.02
mTrop1/Epcam knockout mice develop congenital tufting enteropathy through dysregulation of intestinal E-cadherin/β-catenin. PLoS One (2012) 1.01
Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst (2012) 1.01
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology (2005) 1.01
Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem (2004) 1.00
Methionine sulfoxide reductase A down-regulation in human breast cancer cells results in a more aggressive phenotype. Proc Natl Acad Sci U S A (2010) 1.00
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett (2008) 1.00
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res (2008) 0.99
Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS One (2012) 0.99
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res (2006) 0.99
Oligomerization of DsRed is required for the generation of a functional red fluorescent chromophore. FEBS Lett (2002) 0.99
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res (2004) 0.99
Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer (2004) 0.98
Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim Biophys Acta (2004) 0.98
Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis. Infect Immun (2010) 0.98
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res (2007) 0.98
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res (2002) 0.98
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells. PLoS One (2010) 0.98
The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One (2011) 0.97
Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol (2008) 0.97
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol (2005) 0.97
A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis (2012) 0.96
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther (2007) 0.96
Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res (2009) 0.96
Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp Dermatol (2003) 0.95